Cited by 1,509Chemotherapy-induced cardiotoxicity and mitigationBioactive Compounds and Antitumor AgentsCancer therapeutics and mechanisms

The DOI matches its Crossref record.

Doxorubicin: The Good, the Bad and the Ugly Effect

Carvalho, Cristina, Santos, Renato, Cardoso, Susana, Correia, Sonia, Oliveira, Paulo, Santos, Maria, Moreira, Paula·2009·Current Medicinal Chemistry

DOI 10.2174/092986709788803312

Open this paper in CoChat — free account

Abstract

The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers. Despite extensive clinical utilization, the mechanisms of action of DOX remain under intense debate. A growing body of evidence supports the view that this drug can be a double-edge sword. Indeed, injury to nontargeted tissues often complicates cancer treatment by limiting therapeutic dosages of DOX and diminishing the quality of patients' life during and after DOX treatment. The literature shows that the heart is a preferential target of DOX toxicity. However, this anticancer drug also affects other organs like the brain, kidney and liver. This review is mainly devoted to discuss the mechanisms underlying not only DOX beneficial effects but also its toxic outcomes. Additionally, clinical studies focusing the therapeutic efficacy and side effects of DOX treatment will be discussed. Finally, some potential strategies to attenuate DOX-induced toxicity will be debated.

Integrity signals

Registry

Crossref · 10.2174/092986709788803312

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 701–800 of 1,000

Effect of cell imprinting on viability and drug susceptibility of breast cancer cells to doxorubicin
Shahriyari, F., Janmaleki, M., Sharifi, S., Hesar, M. E., Hoshian, S., Taghiabadi, R., Razaghian, A., Ghadiri, M., Peirovi, A., Mahmoudi, M., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.06.007 · Cited by 16
The diuretic amiloride attenuates doxorubicin-induced chemobrain in rats: Behavioral and mechanistic study
Ali, A. E., Elsherbiny, D. A., Azab, S. S., & El‐Demerdash, E. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.10.002 · Cited by 15
Chitosan-Boric Acid Scaffolds for Doxorubicin Delivery in the Osteosarcoma Treatment
Dornjak, L., Kovačić, M., Ostojić, K., et al. (2022) · Polymers · doi:10.3390/polym14214753 · Cited by 15
Melatonin and metformin counteract cognitive dysfunction equally in male rats with doxorubicin-induced chemobrain
Chunchai, T., Pintana, H., Arinno, A., Ongnok, B., Pantiya, P., Khuanjing, T., Prathumsap, N., Maneechote, C., Chattipakorn, N., & Chattipakorn, S. C. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.11.012 · Cited by 15
Composite Hydrogels with Included Solid-State Nanoparticles Bearing Anticancer Chemotherapeutics
Zhivkov, A. M., Popov, T. T., & Hristova, S. H. (2023) · Gels · doi:10.3390/gels9050421 · Cited by 16
Eupatilin attenuates doxorubicin-induced cardiotoxicity by activating the PI3K-AKT signaling pathway in mice
Lu, Y., Min, Q., Zhao, X., Li, L., Zhao, G., & Dong, J. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04769-1 · Cited by 15
“Despite its effectiveness in the treatment of many can - cers, its clinical application and therapeutic value are greatly impeded due to the cause of life-threatening cardiotoxicity, which eventually leads to cardiac dysfunction and congestive heart failure [2, 3].”
Moringa oleifera Leaves Extract Ameliorates Doxorubicin-Induced Cardiotoxicity via Its Mitochondrial Biogenesis Modulatory Activity in Rats
Patintingan, C. G. H., Louisa, M., Juniantito, V., Arozal, W., Hanifah, S., Wanandi, S. I., & Thandavarayan, R. A. (2023) · Journal of Experimental Pharmacology · doi:10.2147/jep.s413256 · Cited by 15
“Even though doxorubicin is a very efficient anticancer drug, most patients experience cardiotoxicity as a side effect.(1,2) Cardiotoxicity due to doxorubicin can be characterized by the elevation of several cardiac enzyme markers, electrocardiogram abnormalities, and left ventricular systolic dysfunction that might pr…”
Background
Dual-Ligand Synergistic Targeting Anti-Tumor Nanoplatforms with Cascade-Responsive Drug Release
Luo, F., Zhong, T., Chen, Y., Guo, Q., Tao, L., Shen, X., Fan, Y., & Wu, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15072014 · Cited by 15
“+ Ce6 group, implying cardiac injury caused by free DOX [40,41].”
Background
Agomelatine ameliorates doxorubicin-induced cortical and hippocampal brain injury via inhibition of TNF-alpha/NF-kB pathway
Savran, M., Aşcı, S., Gülle, K., Aslankoç, R., Aşçı, H., Karakuyu, N. F., Erzurumlu, Y., & Kaynak, M. (2023) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2023.2291123 · Cited by 16
“Although the heart is the most common organ for adverse effects kidney, liver, and brain toxicities are well-established (Carvalho et al. 2009; Zhu and Lin 2021).”
Background
A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins
Su, H., Jia, J., Mao, Y., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55185-4 · Cited by 15
AICAR confers prophylactic cardioprotection in doxorubicin-induced heart failure in rats
Choksey, A., Carter, R. D., Thackray, B. D., Ball, V., Kennedy, B. W. C., Ha, L. H. T., Sharma, E., Broxholme, J., Castro‐Guarda, M., Murphy, M. P., et al. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.04.011 · Cited by 18
“Doxorubicin (DOX) is a chemotherapeutic agent, which is regularly used to treat solid and haematological malignancies, including breast cancer, ovarian cancer, and acute myeloid leukaemia in both adult and paediatric patients [1].”
Spherical nucleic acids for biomedical applications
Xia, C., Cheng, H., Hou, X., et al. (2024) · Advanced Sensor and Energy Materials · doi:10.1016/j.asems.2024.100117 · Cited by 15
A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells
Xue, P., Yang, X., Liu, Y., et al. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.10.004 · Cited by 15
“However, drug resistance and some side effects like hair loss, bone marrow suppression, nausea, and hand–foot syndrome have limited its effectiveness [27].”
Background
Preclinical Evaluation of an Epidermal Growth Factor Receptor–Targeted Doxorubicin–Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice
Yang, F., Ai, W., Jiang, F., et al. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.10.020 · Cited by 15
“The mice were monitored for up to 60 days after the tumor implantation or euthanized earlier if (1) the mouse was lethargic or sick and therefore unable to feed, (2) the tumor was >2.”
Background
Covalent-reaction-induced interfacial assembly to transform doxorubicin into nanophotomedicine with highly enhanced anticancer efficiency
Qin, C., Fei, J., Cui, G., et al. (2017) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp02543b · Cited by 15
Basic fibroblast growth factor promotes doxorubicin resistance in chondrosarcoma cells by affecting XRCC5 expression
Hsieh, M., Huang, C., Lin, C., Tang, C., Lin, C., Lee, I., Huang, H., & Chen, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23153 · Cited by 15
Aptamers with Self-Loading Drug Payload and pH-Controlled Drug Release for Targeted Chemotherapy
Zeng, Z., Qi, J., Wan, Q., & Zu, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081221 · Cited by 15
Ultrasound responsive Gd-DOTA/doxorubicin-loaded nanodroplet as a theranostic agent for magnetic resonance image-guided controlled release drug delivery of melanoma cancer
Maghsoudinia, F., Akbari-Zadeh, H., Aminolroayaei, F., et al. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106207 · Cited by 15
Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin
Yang, E. Y., Howard, G. R., Brock, A., Yankeelov, T. E., & Lorenzo, G. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.972146 · Cited by 15
“However, the cytotoxic action of doxorubicin (Gewirtz, 1999; Carvalho et al., 2009; McKenna et al., 2017) also induces cell cycle arrest.”
BackgroundInfluential
Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cells
Tacar, O., Indumathy, S., Tan, M. L., Baindur‐Hudson, S., Friedhuber, A. M., & Dass, C. R. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12324 · Cited by 15
“Early clinical assessments during the 1970s([7]) on Dox during phase II and III studies showed common side effects of acute vomiting and nausea, baldness and disturbances to the neurological system (often causing hallucinations and light headedness).”
Background
Protective Effects of Rosmarinic Acid on Doxorubicin-Induced Testicular Damage
Üyetürk, Ü., Üyetürk, U., Fırat, T., et al. (2014) · Chemotherapy · doi:10.1159/000365727 · Cited by 15
DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells
Dinis, J., Silva, V. M. D. S., Gromicho, M., Martins, C., Laires, A., Tavares, P., Rendeiro, P., Torres, F., Rueff, J., & Rodrigues, A. S. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.681654 · Cited by 15
Cytotoxicity of doxorubicin conjugated with C60 fullerene. Structural and in vitro studies
Butowska, K., Kozak, W., Zdrowowicz, M., et al. (2019) · Structural Chemistry · doi:10.1007/s11224-019-01428-4 · Cited by 15
Dual-Effect of Magnetic Resonance Imaging Reporter Gene in Diagnosis and Treatment of Hepatocellular Carcinoma
Zhou, J.-P., Zhou, Q.-M., Shu, G., Wang, X., Lu, Y., Chen, H., Hu, T., Cai, J., Du, Y., & Yu, R. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s257628 · Cited by 15
Sub-chronic administration of doxorubicin to Wistar rats results in oxidative stress and unaltered apoptotic signaling in the lung
Machado, N. G., Baldeiras, I., Pereira, G. C., et al. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.09.027 · Cited by 15
“[1] C.”
BackgroundSelf-citation
Salviae Miltiorrhizae Radix et Rhizoma protects against doxorubicin-induced cardiotoxicity: A systematic review
Yue, M.-Y., Zhao, W.-R., Wang, S.-S., Zhang, J., Shi, W., Tang, J.-Y., & Zhou, Z.-Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157244 · Cited by 15
Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non–muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis
Fukuokaya, W., Kimura, T., Miki, J., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.09.005 · Cited by 14
Aptamer Functionalized Upconversion Nanotheranostic Agent With Nuclear Targeting as the Highly Localized Drug-Delivery System of Doxorubicin
Song, X., Yan, T., Tian, F., Li, F., Ren, L., Li, Q., & Zhang, S. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.639487 · Cited by 14
“However, its short half-life, obvious drug resistance, and serious adverse effects have been main bottlenecks for its clinical applications (Carvalho et al., 2009).”
Background
Tailoring co-assembly loading of doxorubicin in solvent-triggering gel
Zhao, C., Wang, Y., Shi, B., et al. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.06.175 · Cited by 14
Flavonoids from Hippophae rhamnoides Linn. Revert Doxorubicin-Induced Cardiotoxicity through Inhibition of Mitochondrial Dysfunction in H9c2 Cardiomyoblasts In Vitro
Zhou, W., Ouyang, J., Hu, N., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043174 · Cited by 14
“It has efficacy in fighting several solid tumors, including in breast cancer, lung cancer, and leukemia [3,4].”
Background
Characterization of 3D NSCLC Cell Cultures with Fibroblasts or Macrophages for Tumor Microenvironment Studies and Chemotherapy Screening
Garnique, A. M. B., & Machado‐Santelli, G. M. (2023) · Cells · doi:10.3390/cells12242790 · Cited by 14
“Dox is classiﬁed as a topoisomerase II poison [50].”
Background
A mathematical model for predicting the spatiotemporal response of breast cancer cells treated with doxorubicin
Miniere, H. J. M., Lima, E. A. B. F., Lorenzo, G., Hormuth, D. A., Ty, S., Brock, A., & Yankeelov, T. E. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2321769 · Cited by 14
Injectable hyaluronic acid–cyclodextrin-based hydrogels for localized and sustained release of anticancer drugs
Nguyen, D. T., Dang, L. H., Le, H. K., Lien, T., Trân, N. Q., Park, K. D., & Thi, P. L. (2024) · Macromolecular Research · doi:10.1007/s13233-024-00262-w · Cited by 17
Synthesis and evaluation of a bis-3-chloropiperidine derivative incorporating an anthraquinone pharmacophore
Zuravka, I., Sosic, A., Gatto, B., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.08.042 · Cited by 14
Cancer Cell Response to Anthracyclines Effects: Mysteries of the Hidden Proteins Associated with These Drugs
Tylečková, J., Hrabáková, R., Mairychova, K., et al. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131215536 · Cited by 14
“They have been widely used in clinics for the treatment of both solid tumors and hematological malignancies since the early 1960s, when these products of Streptomyces peucetius were first isolated [1].”
Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies
Jamshidi, Z., Zavvar, T. S., Ramezani, M., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121892 · Cited by 14
Targeted inhibition of HER-2 positive breast cancer cells by trastuzumab functionalized pullulan-doxorubicin nanoparticles
Xu, R., Sui, J., Zhao, M., et al. (2022) · Polymer Testing · doi:10.1016/j.polymertesting.2022.107669 · Cited by 14
Achievement of the Selectivity of Cytotoxic Agents against Cancer Cells by Creation of Combined Formulation with Terpenoid Adjuvants as Prospects to Overcome Multidrug Resistance
Zlotnikov, I. D., Dobryakova, N. V., Ezhov, A. A., & Kudryashova, E. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098023 · Cited by 14
“The mechanism of action of Dox includes [13,14]: (1) intercalation of Dox into DNA base pairs, causing DNA strands to break and inhibiting the synthesis of both DNA and RNA; (2) Dox inhibits the enzyme topoisomerase II, causing disruption of DNA unwinding for transcription and replication, DNA damage, and the inductio…”
Background
Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment
Zhang, J., Guo, Y., Fang, H., Guo, X., & Zhao, L. (2023) · Autoimmunity · doi:10.1080/08916934.2023.2259126 · Cited by 14
“…has been reported to exert strong antitumor effects and can successfully induce apoptosis in a variety of malignancies, including acute leukemia, DLBCL, breast, lung, ovarian, sarcoma, bladder, thyroid, prostate, head and neck squamous cell carcinoma, testicular, gastric, liver, and others [24–27].”
Background
Different Doxorubicin Formulations Affect Plasma 4-Hydroxy-2-Nonenal and Gene Expression of Aldehyde Dehydrogenase 3A1 and Thioredoxin Reductase 2 in Rat
Hlaváčová, M., Gumulec, J., Stračina, T., et al. (2015) · Physiological Research · doi:10.33549/physiolres.933223 · Cited by 14
“…(DOX) is one of the most frequently used antitumor drugs, with high activity against an extensive variety of malignancies, both hematological and solid tumors – gynecological, urogenital, endocrine, stomach cancer, as well as Ewing and Kaposi’s sarcomas (reviewed by Carvalho et al. 2009).”
Background
Toxicological profile and safety pharmacology of a single dose of fibroblast activation protein-α-based doxorubicin prodrug
Huang, S., Zhang, Y., Zhong, J., Pan, Y., Cai, S., & Xu, J. H. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000593 · Cited by 15
Fullerenol/iron nanocomposite diminishes doxorubicin-induced toxicity
Seke, M., Petrović, D., Labudović‐Borović, M., Borišev, I. Đ., Novaković, M. M., Rakočević, Z. L., & Djordjevic, A. N. (2019) · Journal of Nanoparticle Research · doi:10.1007/s11051-019-4681-4 · Cited by 14
“Doxorubicin has been proclaimed for being one of the most potent, of the Food and Drug Administration-approved, chemotherapeutic drugs (Carvalho et al. 2009).”
Background
Sesamol Upregulates Death Receptors and Acts as a Chemosensitizer in Solid Ehrlich Carcinoma Model in Mice
Elrazik, N. A. A., El‐Mesery, M., El-Karef, A. A., Eissa, L. A., & Gayar, A. M. E. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2020.1871496 · Cited by 14
Recent doxorubicin-conjugates in cancer drug delivery: Exploring conjugation strategies for enhanced efficacy and reduced toxicity
Gautam, S., Joshi, S., Jindal, P., Patel, P., Pal, R. R., Kumar, M., Gupta, G. D., & Kurmi, B. D. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125556 · Cited by 14
Lipid-based nanoparticles external triggered release strategies in cancer nanomedicine
Alhussan, A., Ho, L., Zhang, Y., Fan, H. D. E., Momeni, A., Brimacombe, C. A., & Cullis, P. R. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03704-4 · Cited by 17
“Chemotherapy involves administering a small-molecule drug that interferes with cellular processes involved in active cell division, disproportionately targeting fast-dividing cells such as cancer cells [3, 4].”
Morpholino-driven blockade of Dkk-1 in osteosarcoma inhibits bone damage and tumour expansion by multiple mechanisms
Pan, S., Cesarek, M. R., Godoy, C., Co, C. M., Schindler, C., Padilla, K., Haskell, A. W., Barreda, H., Story, C., Poole, R., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01764-z · Cited by 13
“This observation is not surprising, given that one mechanism of DRB is the generation of ROS which destroys tumour cells [32].”
Background
PCSK9 conjugated liposomes for targeted delivery of paclitaxel to the cancer cell: A proof-of-concept study
Charbe, N. B., Lagos, C. F., Vilos, C., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113428 · Cited by 13
Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic–DEVD–Doxorubicin Conjugate for Targeted Cancer Therapy
Yang, S.-B., Lee, D.-N., Lee, J.-H., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00490 · Cited by 13
SESN2-Mediated AKT/GSK-3β/NRF2 Activation to Ameliorate Adriamycin Cardiotoxicity in High-Fat Diet–Induced Obese Mice
Gao, T., Wang, J., Xiao, M., Wang, J., Wang, S., Tang, Y., Zhang, J., Lu, G., Guo, Y., Guo, Y., et al. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0156 · Cited by 13
“Ample evidence indicates that ADR can lead to heart failure and even death in patients (Carvalho et al., 2009).”
Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications
Kwok, C., & Nolan, M. T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1150569 · Cited by 14
“Acutely, it can cause arrhythmias and hypotension, while in the long term, doxorubicin can contribute to cardiac hypertrophy and manifest as symptoms of heart failure (46).”
n-3 PUFAs synergistically enhance the efficacy of doxorubicin by inhibiting the proliferation and invasion of breast cancer cells
Gurav, P., Patade, T. P., Hajare, S., et al. (2023) · Medical Oncology · doi:10.1007/s12032-023-02229-w · Cited by 13
Rhein potentiates doxorubicin in treating triple negative breast cancer by inhibiting cancer-associated fibroblasts
Xu, S., Zheng, S., Ma, N., et al. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116139 · Cited by 13
Potential of Natural Phenolic Compounds against Doxorubicin-Induced Chemobrain: Biological and Molecular Mechanisms Involved
Serini, S., & Calviello, G. (2024) · Antioxidants · doi:10.3390/antiox13040486 · Cited by 14
“It is It is used as a chemotherapeutic agent in a variety of tumors [38], being able to exert strong cytotoxic effects, especially in highly proliferating cells. used as a chemotherapeutic agent in a variety of tumors [38], being able to exert strong cytotoxic effects, especially in highly…”
Background
Strategies to make human skin models based on cellular senescence for ageing research
Shakel, Z., Lima, S. A. C., & Reis, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102430 · Cited by 17
“Doxorubicin is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers (Carvalho et al., 2009).”
Background
Influence of silver nanoparticles’ size on their direct interactions with doxorubicin and its biological effects
Gołuński, G., Konkel, K., Galikowska‐Bogut, B., Bełdzińska, P., Bury, K., Zakrzewski, M., Butowska, K., Sądej, R., & Piosik, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-69724-6 · Cited by 13
Enhancing localized chemotherapy with anti-angiogenesis and nanomedicine synergy for improved tumor penetration in well-vascularized tumors
Souri, M., Elahi, S., Kashkooli, F. M., Kohandel, M., & Soltani, M. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00467-w · Cited by 13
“For instance, repeated administration of doxorubicin has been reported to cause serious damage to the cardiovascular system 11 .”
The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models
Stasiak, P., Sopel, J., Lipowicz, J. M., Rawłuszko-Wieczorek, A. A., Korbecki, J., & Januchowski, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031124 · Cited by 13
Chlorogenic acid potentiates antitumor effect of doxorubicin through upregulation of death receptors in solid Ehrlich carcinoma model in mice
Elrazik, N. A. A., El‐Mesery, M., El-Karef, A. A., Eissa, L. A., & Gayar, A. M. E. (2019) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2019.1682331 · Cited by 14
DNA Double-Strand Breaks in Murine Mammary Tumor Cells Induced by Combined Treatment with Doxorubicin and Controlled Stable Cavitation
Fant, C., Granzotto, A., Mestas, J., Ngo, J., Lafond, M., Lafon, C., Foray, N., & Padilla, F. R. (2021) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2021.05.028 · Cited by 13
Dextran-polylactide micelles loaded with doxorubicin and DiR for image-guided chemo-photothermal tumor therapy
Shi, Y., Tan, R., Yu, C., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.141 · Cited by 13
Microbubble-Assisted Ultrasound for Imaging and Therapy of Melanoma Skin Cancer: A Systematic Review
Avry, F., Mousset, C., Oujagir, E., et al. (2022) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2022.06.021 · Cited by 13
Layer-by-layer development of chitosan/alginate-based platelet-mimicking nanocapsules for augmenting doxorubicin cytotoxicity against breast cancer
Ibrahim, A., Khalil, I. A. H., Mahmoud, M. Y., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.107 · Cited by 13
New Nanosized Systems Doxorubicin—Amphiphilic Copolymers of N-Vinylpyrrolidone and (Di)methacrylates with Antitumor Activity
Викторовна, К. С., Ignatiev, V. M., Emel’yanova, N. S., Kurmaz, V. A., Конев, Д. В., Балакина, А. А., & Terentyev, A. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122572 · Cited by 12
Gold Nanosystems Covered with Doxorubicin/DNA Complexes: A Therapeutic Target for Prostate and Liver Cancer
Giráldez‐Pérez, R. M., Grueso, E., Montero‐Hidalgo, A. J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415575 · Cited by 13
MicroRNA-631 Resensitizes Doxorubicin-Resistant Chondrosarcoma Cells by Targeting Apelin
Chen, J., Shih, H.-C., Lin, C., Guo, J., Huang, C., Huang, H., Chong, Z.-Y., & Tang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010839 · Cited by 14
Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA
Zhao, J., Mu, X., Hou, X., Zhang, X., Li, P., & Jiang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1111855 · Cited by 13
The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin
Moyal, L., Feldbaum, N., Goldfeiz, N., Rephaeli, A., Nudelman, A., Weitman, M., Tarasenko, N., Gorovitz, B., Maron, L., Yehezkel, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146115 · Cited by 13
“However, its use is complicated by dose-limiting cardiotoxicity and therefore requires combination therapy [50].”
Background
Grape seed and skin extract protects kidney from doxorubicin-induced oxidative injury
Mokni, M. (2016) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps/29/3/03.05.2016/27-3257/961-968 · Cited by 13
Doxorubicin binds to duplex RNA with higher affinity than ctDNA and favours the isothermal denaturation of triplex RNA
Rubio, A. R., Busto, N., Leal, J. M., et al. (2016) · RSC Advances · doi:10.1039/c6ra21387a · Cited by 13
Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer
Hu, Y., Wu, C., Zhu, C., Fu, Q., Guo, J., Deng, L., He, Y., Yang, D., Cheng, Y., & Gao, X. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.013 · Cited by 13
Design, synthesis and anticancer activity of 2-amidomethoxy-1,4-naphthoquinones and its conjugates with Biotin/polyamine
Manickam, M., Boggu, P. R., Pillaiyar, T., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127685 · Cited by 13
Solid Lipid Particles for Lung Metastasis Treatment
Valdivia, L., García‐Hevia, L., Bañobre‐López, M., Gallo, J., Valiente, R., & Fanárraga, M. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010093 · Cited by 13
“However, DOX use is currently decreasing due to its side effects, which include cardiotoxicity and nephrotoxicity [27,28].”
Background
Biochemical effects of spirulina platensis against oxidative stress caused by doxorubicin
Hassanen, M., Mahfouz, M., Farid, A., & Fadlullah, A. (2015) · Benha Veterinary Medical Journal · doi:10.21608/bvmj.2015.32493 · Cited by 13
The role of ferroptosis in doxorubicin-induced cardiotoxicity – An update
Bhadra, P., Yadav, P., Kaur, S., Hanumantharayudu, P. T., & Arunachalam, S. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123945 · Cited by 12
Methyl Gallate Mitigates Doxorubicin-Induced Peripheral Cytopenias: A Preclinical Experimental Study
Ahmed, A. Z., Shetty, P., Satyam, S. M., et al. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.00788 · Cited by 12
Molecular tests for prediction of tumor sensitivity to cytotoxic drugs
Имянитов, Е. Н., & Iyevleva, A. G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.021 · Cited by 12
FGF10 mitigates doxorubicin-induced myocardial toxicity in mice via activation of FGFR2b/PHLDA1/AKT axis
Zhou, D., Deng, L., Feng, X., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01101-x · Cited by 12
“For decades, doxorubicin (DOXO) has been the ﬁ rst-line chemotherapeutic treatment for various types of malignancies, such as bladder cancer, breast cancer, leukemia, and lymphoma [1, 2].”
Background
Insights into the therapeutic outcomes of trimetazidine/doxorubicin combination in Ehrlich solid-phase carcinoma mouse tumor model
Abdeljalil, S. M., Wahdan, S. A., Elghazaly, H. A., & Tolba, M. F. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121874 · Cited by 13
Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice
Liu, Y., Reiken, S. R., Dridi, H., Yuan, Q., Mohammad, K. S., Trivedi, T., Miotto, M., Wedderburn-Pugh, K., Sittenfeld, L. R., Kerley, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf8977 · Cited by 13
“…topoisomerase II inhibitors and is one of the most effective and fundamental anticancer antibiotic agents approved by the U.S. Food and Drug Administration for the treatment of diverse types of cancer, including breast cancer, metastatic solid tumors, lymphomas, and Kaposi ’ s sarcoma ( 90 – 93 ).”
Background
Diosmin alleviates doxorubicin-induced chemobrain in rats via inhibition of oxido-inflammation, apoptosis and modulation of autophagy
Oyovwi, M. O., Faith, F. Y., Ejiro, O. P., Uchechukwu, J. G., Olowe, G. T., Oghenetega, O. B., Emojevwe, V. O., Edesiri, T. P., Rotu, R. A., Rotu, R. A., et al. (2023) · Brain Disorders · doi:10.1016/j.dscb.2023.100111 · Cited by 12
Ameliorative impacts of propolis against testicular toxicity promoted by doxorubicin
Syaad, K. M. A. (2024) · Veterinary World · doi:10.14202/vetworld.2024.421-426 · Cited by 12
“Doxorubicin (DOX) is a highly effective lipid-coated anticancer drug used in chemotherapy [11–13].”
Background
Research progress on the role and mechanism of Sirtuin family in doxorubicin cardiotoxicity
Zhang, X., Huang, C., Hou, Y., Jiang, S., Zhang, Y., Wang, S., Chen, J., Lai, J., Wu, L., Duan, H., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155673 · Cited by 12
Oxyresveratrol and/or Dapagliflozin Attenuate Doxorubicin-Induced Nephrotoxicity via Modulation of PPAR-γ/Nrf-2/HO-1, NF-κB/TNF-α/Keap-1, and Bcl-2/Caspase-3/ATG-5 signaling pathways in rats
El-Sawy, W. S. M., Khalaf, M. M., El‐Bahrawy, A. H., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03608-4 · Cited by 12
“Among other cancers, solid tumors, hematological malignancies, and breast cancer can all be more successfully treated with the anthracycline antibiotic DOX (Carvalho et al. 2009).”
Synergistic Cancer treatment strategies using platinum-porphyrin conjugates
Ali, M. A., Chu, K. H., Ryu, D. Y., & Jang, W. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216873 · Cited by 12
Silencing NOB1 enhances doxorubicin antitumor activity of the papillary thyroid carcinoma in vitro and in vivo
Liu, J., Dong, B., Wang, P., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.3730 · Cited by 12
“However, the clinical impact of DOX on thyroid cancer remains poor due to a high degree of chemoresistance (5,6).”
Background
Retracted
Molecular beacon immobilized on graphene oxide for enzyme-free signal amplification in electrochemiluminescent determination of microRNA
Wang, J., Zhang, L., Lü, L., et al. (2019) · Microchimica Acta · doi:10.1007/s00604-019-3252-9 · Cited by 12
The Product of Matrix Metalloproteinase Cleavage of Doxorubicin Conjugate for Anticancer Drug Delivery: Calorimetric, Spectroscopic, and Molecular Dynamics Studies on Peptide–Doxorubicin Binding to DNA
Butowska, K., Żamojć, K., Kogut, M., Kozak, W., Wyrzykowski, D., Wiczk, W. M., Czub, J., Piosik, J., & Rak, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186923 · Cited by 13
“Moreover, DOX can lead to several side effects that mainly affect the brain, kidneys, and liver [13].”
Background
Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase
Yang, R., Guo, Z., Zhao, Y., Ma, L., Li, B., & Yang, C. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00590-1 · Cited by 12
“However, despite its success in improving cancer survival rates, long-term ADR treatment may lead to drug resistance and side effects [7, 8].”
Background
Thioredoxin-1 Activation by Pterostilbene Protects Against Doxorubicin-Induced Hepatotoxicity via Inhibiting the NLRP3 Inflammasome
Tan, S., Bai, J., Xu, M., Zhang, L., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841330 · Cited by 12
“However, recent studies showed that DOX causes unanticipated side-effects such as nausea, vomiting, extravasation, severe hepatotoxicity, and cardiotoxicity which limit its use in clinical practice (Carvalho et al., 2009; Kolarovic et al., 2009).”
Background
Development and evaluation of PLA based hybrid block copolymeric nanoparticles for systemic delivery of pirarubicin as an anti-cancer agent
Anees, M., Tiwari, S., Mehrotra, N., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121761 · Cited by 12
Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology
Wang, H., He, Y., Jian, M., Fu, X., Cheng, Y., He, Y., Fang, J., Li, L., & Zhang, D. (2022) · Molecules · doi:10.3390/molecules27217480 · Cited by 11
Extended-release of doxorubicin through green surface modification of gold nanoparticles: in vitro and in ovo assessment
Asariha, M., Kiaie, S. H., Izadi, S., et al. (2022) · BMC Chemistry · doi:10.1186/s13065-022-00895-x · Cited by 12
“For instance, irreversible cardiomyopathy has been reported due to the cumulative drug dose and consequent cell damage resulting from the enhanced free radical in myocytes [5, 6].”
Background
An Magnetic-Targeting Nano-Diagnosis and Treatment Platform for TNBC
Zhang, M., Bao, S., Qiu, G., et al. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s387793 · Cited by 12
“Although the effect of DOX in the tumors treatment is considerable, it often causes serious adverse reactions and drug resistance.(13) Therefore, it is a challenging goal to develop new cancer treatment options that can not only effectively fight cancer but also reduce toxic and side effects.”
Background
Different Mechanisms in Doxorubicin-Induced Cardiomyopathy: Impact of BRCA1 and BRCA2 Mutations
Nguyen, H. C., Frisbee, J. C., & Singh, K. K. (2024) · Hearts · doi:10.3390/hearts5010005 · Cited by 11
“It has been generally established that free radical-associated DNA damage is more likely to occur when Dox concentration breaches the tolerance dosage [14].”
Background
Cytotoxic, apoptotic, and sensitization properties of ent ‐kaurane‐type diterpenoids from Croton tonkinensis Gagnep on human liver cancer HepG2 and Hep3b cell lines
Pham, M. Q., Iscache, A. L., Pham, Q. L., et al. (2015) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12176 · Cited by 12
Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia
Huang, Z., Wang, J., Qian, J., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6470 · Cited by 12
“Daunorubicin (DNR) is a chemotherapeutic of the anthracycline family, which is used as a treatment for acute leukemia (1).”
Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral Activity
Diab, D. E. H., Clerc, P., Serhan, N., et al. (2018) · Nanomaterials · doi:10.3390/nano8070468 · Cited by 12
Intercalator-Induced DNA Superstructure Formation: Doxorubicin and a Synthetic Quinoxaline Derivative
Mahata, T., Chakraborty, J., Kanungo, A., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00613 · Cited by 12
Modelling of Implantable Drug Delivery System in Tumor Microenvironment Using Molecular Communication Paradigm
Al-Zu'bi, M. M., & Mohan, A. S. (2019) · IEEE Access · doi:10.1109/access.2019.2944257 · Cited by 12
“The anticancer drug (DOX) is chosen because it is widely used in chemotherapy due to its efficacy in destroying a wide range of cancers [31].”
Background
Synthesis, characterization and albumin binding capabilities of quinizarin containing ternary cobalt(III) complexes
Kozsup, M., Dömötör, O., Nagy, S., et al. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.110963 · Cited by 12

Authors: Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P.
Affiliations: Centro de Neurociências e Biologia Celular (PT)
Corresponding author: Moreira, Paula
ORCID: Carvalho, Cristina
Santos, Renato
Cardoso, Susana
Oliveira, Paulo
Santos, Maria
Moreira, Paula
Venue: Current Medicinal Chemistry
Publisher: Bentham Science Publishers Ltd.
Published: 2009-09-01
Volume: 16
Issue: 25
Pages: 3267-3285
ISSN: 0929-8673 (ISSN-L)
DOI: 10.2174/092986709788803312
OpenAlex: W2102897174
Cited by: 1,509
References: 0
Citations by year: 2026: 102 · 2025: 147 · 2024: 174 · 2023: 169 · 2022: 153 · 2021: 150 · 2020: 120 · 2019: 85 · 2018: 84 · 2017: 53 · 2016: 63 · 2015: 62 · 2014: 43 · 2013: 35 · 2012: 29
FWCI: 14.12
Type: journal article
Language: en
Open access: closed
Locations: Current Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords: doxorubicin, anthracyclines, cardiotoxicity, drug toxicity mechanisms, anticancer mechanism, neurotoxicity, nephrotoxicity, hepatotoxicity, chemotherapy side effects
MeSH terms: Antibiotics, Antineoplastic, Doxorubicin, Humans, Molecular Conformation, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Doxorubicin: The Good, the Bad and the Ugly Effect

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks